AVTX Stock Overview
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Notes are coming soon
Avalo Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.00|
|52 Week High||US$12.60|
|52 Week Low||US$2.42|
|1 Month Change||-20.87%|
|3 Month Change||-34.43%|
|1 Year Change||-63.88%|
|3 Year Change||-91.56%|
|5 Year Change||-88.89%|
|Change since IPO||-91.67%|
Recent News & Updates
|AVTX||US Biotechs||US Market|
Return vs Industry: AVTX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: AVTX underperformed the US Market which returned -9.7% over the past year.
|AVTX Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: AVTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AVTX's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis.
Avalo Therapeutics, Inc. Fundamentals Summary
|AVTX fundamental statistics|
Is AVTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVTX income statement (TTM)|
|Cost of Revenue||US$29.46m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.41|
|Net Profit Margin||-293.41%|
How did AVTX perform over the long term?See historical performance and comparison